接受手术切除后辅助化疗的非小细胞肺癌患者术后放疗与临床显著心血管疾病风险:韩国全国队列研究
该韩国全国队列研究纳入2007至2017年接受治愈性手术及辅助化疗的非小细胞肺癌患者共11141例,其中1334例接受术后放疗。中位随访70.6个月后,心力衰竭最常见(5.3%),其次为心房颤动(4.5%)、卒中(4.1%)和肺栓塞(3.5%);所有临床显著心血管疾病发生率在术后放疗与否间无差异,倾向评分匹配后结果不变。
要点
- 中位随访70.6个月,心力衰竭为最常见心血管疾病(5.3%),其次为心房颤动(4.5%)、卒中(4.1%)和肺栓塞(3.5%)。
- 所有临床显著心血管疾病发生率在术后放疗组与未放疗组间无差异,倾向评分匹配后结果不变。
- 年龄≥65岁、合并高血压和缺血性心脏病史是与心力衰竭和心房颤动发生最相关的因素。
核心结论
- 术后放疗对无基础心脏病的非小细胞肺癌患者各种心血管疾病发生无显著影响。
研究设计与样本
- 韩国全国人口数据库队列研究,纳入2007至2017年诊断的非小细胞肺癌接受治愈性手术及辅助化疗的患者,排除既往心力衰竭、心房颤动或心脏手术者,最终分析11141例,其中1334例接受术后放疗。
主要发现
- 主要不良心脏事件多发生在诊断后3至4年内。
- 中位随访70.6个月后,心力衰竭最常见(5.3%),其次为心房颤动(4.5%)、卒中(4.1%)和肺栓塞(3.5%)。
- 所有临床显著心血管疾病发生率在术后放疗与否间无差异,倾向评分匹配比较后结果不变。
- 年龄≥65岁、合并高血压和缺血性心脏病史是与心力衰竭和心房颤动发生最相关的因素。
- 按所提出的评分分层后,无亚组显示术后放疗增加心血管疾病发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no large-scale datasets that analyze the relationship between postoperative radiotherapy (PORT) and various cardiovascular diseases (CVDs) in patients with locally advanced non-small cell lung cancer (NSCLC). Therefore, we aimed to investigate the incidences of CVDs with PORT using a national population-based database. METHODS: Patients diagnosed with NSCLC who underwent curative surgery followed by adjuvant chemotherapy were included from 2007 to 2017. Patients with a prior diagnosis of heart failure (HF), atrial fibrillation (AFib), or heart surgery were excluded. A total of 11,141 patients were included in the final analysis. PORT was used in 1334 patients. Most patients received lobectomy with mediastinal lymph node dissection. RESULTS: Major adverse cardiac events mostly occurred within 3-4 years from the diagnosis. After the median follow-up duration of 70.6 months, HF was the most diagnosed disease (5.3 %), followed by AFib (4.5 %), stroke (4.1 %), and pulmonary embolism (3.5 %). All the incidences of clinically significant CVDs did not differ by PORT. This result remained unchanged after the propensity score matching comparison. Age ≥ 65, underlying hypertension, and history of ischemic heart disease were the most related factors to the occurrence of HF and AFib. No significant difference in CVD-free survivals according to PORT status was observed. When stratified by proposed scoring, there were no subgroups showed increased incidence by PORT. CONCLUSIONS: These results suggest that PORT had no significant impact on various CVD occurrences in NSCLC patients without underlying heart disease.
引用
- Kwon J, Kim BH. Risk of clinically significant cardiovascular disease associated with postoperative radiotherapy in non-small cell lung cancer patients receiving surgical resection followed by adjuvant chemotherapy: A Korean nationwide cohort study. Radiother Oncol. 2024. PMID: 38522599. doi:10.1016/j.radonc.2024.110241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。